<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117661</url>
  </required_header>
  <id_info>
    <org_study_id>L-Carnitine-01</org_study_id>
    <nct_id>NCT02117661</nct_id>
  </id_info>
  <brief_title>Carnitine for the Treatment of Atherosclerosis.</brief_title>
  <acronym>ECoM</acronym>
  <official_title>ECoM Study: Effect of Carnitine Supplementation on Progression of Carotid Plaque in the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Amer Johri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is one of the main causes of the metabolic syndrome, a condition which is becoming&#xD;
      more common in Canada and worldwide. Metabolic syndrome is a name for a group of heart&#xD;
      disease risk factors that occur together: obesity, diabetes, high blood pressure, and high&#xD;
      cholesterol. These patients have a high risk of developing narrowing and blockages of blood&#xD;
      vessels which occur when fat and cholesterol build up in the walls of blood vessels and form&#xD;
      plaque. This is called atherosclerosis. Plaque buildup leads to stroke, heart attacks, and&#xD;
      death. We do not understand the underlying mechanisms of the metabolic syndrome and we do not&#xD;
      have a treatment for it. L-carnitine, a dietary supplement, has been shown to treat some&#xD;
      components of the metabolic syndrome, but its benefit to reduce plaque in the blood vessels&#xD;
      has never been studied. Recently there has been some controversy because a new study showed&#xD;
      that L-carnitine could make heart disease worse in some patients. Our goal is to study&#xD;
      whether supplementation with L-carnitine does in fact prevent or reduce buildup of plaque in&#xD;
      blood vessels of patients with the metabolic syndrome. This novel therapy has the potential&#xD;
      to decrease the burden of heart disease in obese and diabetic patients with the metabolic&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Question: Does L-carnitine (L-C) therapy slows down and/or regress atherosclerosis,&#xD;
      as measured by total plaque volume (TPV) assessed by 3-dimensional (3D) carotid ultrasound in&#xD;
      patients with metabolic syndrome? We hypothesize that L-C will regress atherosclerotic plaque&#xD;
      formation.&#xD;
&#xD;
      To assess our primary outcome of L-C induced atherosclerosis regression, we anticipate a&#xD;
      significant percent (%) difference in carotid total plaque volume (TPV) over six months of&#xD;
      L-C treatment, compared to placebo. For our secondary outcome, we expect to show that L-C&#xD;
      therapy compared to placebo, induces a reduction in the proportion of small-sized LDL and an&#xD;
      increase in large LDL particles. As small dense LDL particles are more atherogenic than large&#xD;
      buoyant ones, this would suggest a mechanism contributing to the atherosclerosis reduction&#xD;
      induced by L-C therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotid Total Plaque Volume</measure>
    <time_frame>Six months</time_frame>
    <description>Carotid 3D ultrasound scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL size profile</measure>
    <time_frame>Six months</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>L-carnitine capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg daily (2x 500 mg capsules twice a day - BID) for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2x capsules twice a day - BID (4 total per day) for six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnitine capsules</intervention_name>
    <description>Oral</description>
    <arm_group_label>L-carnitine capsules</arm_group_label>
    <other_name>levocarnitine</other_name>
    <other_name>carnitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose capsules</intervention_name>
    <description>oral</description>
    <arm_group_label>Cellulose capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study Population: Patients, followed in our clinics for cardiovascular disease (CVD)&#xD;
        prevention, fulfilling diagnosis criteria for metabolic syndrome (MetS) will be recruited.&#xD;
        Eligibility will require a 2 step process as described.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        STEP 1: Initial screening; BP, weight and fasting blood samples will be obtained.&#xD;
&#xD;
          1. Men and women, &gt;18 years, meeting the criteria for clinical diagnosis of MetS,&#xD;
             according to the International Diabetes Federation (IDF) harmonized definition, where&#xD;
             any 3 of the 5 following risk factors cut points constitutes a diagnosis of MetS:&#xD;
&#xD;
               1. Elevated waist circumference: Population- and country-specific definitions;&#xD;
                  Health Canada recommends males 102 cm and women 88cm.&#xD;
&#xD;
               2. Elevated triglycerides: 150 mg/dL (1.7 mmol/L).&#xD;
&#xD;
               3. Reduced HDL: 40 mg/dL (1.0 mmol/L) in males; 50 mg/dL (1.3 mmol/L) in females or&#xD;
                  treated.&#xD;
&#xD;
               4. Elevated BP: Systolic 130 and/or diastolic 85 mm Hg or treated.&#xD;
&#xD;
               5. Elevated fasting glucose: 100 mg/dL (5.6 mmol/L), or HbA1c ≥6.2%, or treated.&#xD;
&#xD;
          2. Willing to provide informed consent. STEP 2: Baseline plaque volume ≥50 mm3 by 3D US,&#xD;
             to ensure sufficient detectable plaque. This will be measured after consent (at Step&#xD;
             1), but prior to randomization/enrolment (Step 2).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Individuals who have had a change in statin and/or diabetes medication therapy or&#xD;
             dosing in the last three months;&#xD;
&#xD;
          2. Who are actively having an unstable arrhythmia, angina or heart attack (untreated&#xD;
             and/or unstable patients): symptomatic heart failure (NYHA 2 or greater); renal&#xD;
             failure (GFR &lt;50 mL/min/1.73m2);&#xD;
&#xD;
          3. Known severe abnormal blood biochemistries: Na &lt;100 or &gt;150 mmol/L, K &lt;2 or &gt;5 mmol/L,&#xD;
             Total Serum Ca &gt;3 mmol/L;&#xD;
&#xD;
          4. Known severe liver disease: AST &gt;100 U/L, ALT &gt;80 U/L, or a diagnosis of cirrhosis&#xD;
             (Child Pugh Class A to C);&#xD;
&#xD;
          5. Known severe anemia: HgB &lt;70 g/L;&#xD;
&#xD;
          6. Have endocrine disorders, e.g. Cushing's disease, hyper- or hypo-thyroidism;&#xD;
&#xD;
          7. Any condition expected to limit survival to less than six (6) months (ex. malignant&#xD;
             tumor);&#xD;
&#xD;
          8. A condition limiting adherence to study procedure (i.e. alcoholism, drug addiction,&#xD;
             known poor adherence, severe mental disorder);&#xD;
&#xD;
          9. Concomitant treatment with: anticonvulsants; L-C or derivatives; Acenocoumarol&#xD;
             (Sintrom) and Warfarin (Coumadin) anticoagulants and vitamin K antagonists; &gt;1g fish&#xD;
             oil; and/or thyroid treatment;&#xD;
&#xD;
         10. A seizure disorder or at risk of seizure (CNS mass or medications that lower seizure&#xD;
             threshold); receiving treatments for cancer or HIV infection (secondary L-C&#xD;
             deficiency);&#xD;
&#xD;
         11. Currently pregnant or breastfeeding;&#xD;
&#xD;
         12. A history of allergy or intolerance to L-C or derivatives;&#xD;
&#xD;
         13. Vegetarians (do not eat animal flesh) due to potential for altered L-C metabolism;&#xD;
&#xD;
         14. Patients who have had a carotid surgery (ie. endarterectomy (CEA) or stent) or who are&#xD;
             scheduled to receive carotid surgery during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amer M Johri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.David Spence, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robarts Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daren K Heyland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's University, Cardiovascular Imaging Network at Queen's (CINQ), Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Institute, Stroke Prevention &amp; Atherosclerosis Research Centre (SPARC)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cinqlab.com</url>
    <description>Cardiovascular Imaging Network at Queen's (CINQ)</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Amer Johri</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>L-carnitine</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Carotid</keyword>
  <keyword>Plaque</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Vascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

